Summary

Oxygen Biotherapeutics, Inc. (OBI) develops medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company is developing proprietary Oxycyte, is a perfluorocarbon (PFC) therapeutic oxygen carrier and intended to improve oxygen delivery to damaged tissues. The technology is being studied as the potential treatment for traumatic brain injury, decompression sickness, wound treatment and stroke. The company also develops a range of topical PFC based gels and creams for dermatologic conditions and potentially wound care. It has entered into several partnerships and collaborations to advance its various products under development through commercialization. OBI is headquartered in Durham, North Carolina, the US.

Oxygen Biotherapeutics, Inc. (OXBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Table of Contents

Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 4
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare Deals By Type, 2008 to YTD 2014 5
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Region, 2008 to YTD 2014 6
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2008 to YTD 2014 7
Oxygen Biotherapeutics, Inc., Medical Devices Deals, 2008 to YTD 2014 8
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals Summary, 2008 to YTD 2014 9
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deal Details 11
Asset Purchase 11
Oxygen Biotherapeutics Completes Acquisition Of Certain Assets Of Phyxius Pharma For US$4.8 Million 11
Partnerships 13
Oxygen Biotherapeutics Enters Into Co-Development Agreement With Aurum Biosciences 13
Oxygen Biotherapeutics Signs Research Agreement With Hackensack University Medical Center 15
Oxygen Biotherapeutics Enters Into Joint Venture Agreement With Virginia Commonwealth University 16
Licensing Agreements 17
Oxygen Biotherapeutics Enters Into Licensing Agreement With Valor For Dermacyte 17
Synthetic Blood International Enters Into Licensing Agreement With Virginia Commonwealth University 18
Equity Offering 19
Oxygen Biotherapeutics Completes Private Placement Of Shares Upon Exercise Of Warrants 19
Oxygen Biotherapeutics Completes Private Placement Of 8% Series D Preferred Stock For US$4.6 Million 20
Oxygen Biotherapeutics Completes Public Offering Of Units For US$5.4 Million 21
Oxygen Biotherapeutics Completes Private Placement Of Shares For US$2 Million 23
Oxygen Biotherapeutics Completes Public Offering Of Units For US$3.5 Million 25
Oxygen Biotherapeutics Completes Registered Direct Offering Of Common Stock For US$5 Million 27
Oxygen Biotherapeutics Completes Second Tranche Of Private Placement Of US$3 Million 29
Debt Offering 31
Oxygen Biotherapeutics Completes Private Placement Of Unregistered Convertible Notes For US$4.9 Million 31
Oxygen Biotherapeutics, Inc. - Key Competitors 32
Key Employees 33
Locations And Subsidiaries 34
Head Office 34
Other Locations and Subsidiaries 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables

Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Key Facts, 2013 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Region, 2008 to YTD 2014 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2008 to YTD 2014 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 4
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare Deals By Type, 2008 to YTD 2014 5
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Region, 2008 to YTD 2014 6
Oxygen Biotherapeutics, Inc., Deals By Therapy Area, 2008 to YTD 2014 7
Oxygen Biotherapeutics, Inc., Medical Devices Deals, 2008 to YTD 2014 8
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals Summary, 2008 to YTD 2014 9
Oxygen Biotherapeutics Completes Acquisition Of Certain Assets Of Phyxius Pharma For US$4.8 Million 11
Oxygen Biotherapeutics Enters Into Co-Development Agreement With Aurum Biosciences 13
Oxygen Biotherapeutics Signs Research Agreement With Hackensack University Medical Center 15
Oxygen Biotherapeutics Enters Into Joint Venture Agreement With Virginia Commonwealth University 16
Oxygen Biotherapeutics Enters Into Licensing Agreement With Valor For Dermacyte 17
Synthetic Blood International Enters Into Licensing Agreement With Virginia Commonwealth University 18
Oxygen Biotherapeutics Completes Private Placement Of Shares Upon Exercise Of Warrants 19
Oxygen Biotherapeutics Completes Private Placement Of 8% Series D Preferred Stock For US$4.6 Million 20
Oxygen Biotherapeutics Completes Public Offering Of Units For US$5.4 Million 21
Oxygen Biotherapeutics Completes Private Placement Of Shares For US$2 Million 23
Oxygen Biotherapeutics Completes Public Offering Of Units For US$3.5 Million 25
Oxygen Biotherapeutics Completes Registered Direct Offering Of Common Stock For US$5 Million 27
Oxygen Biotherapeutics Completes Second Tranche Of Private Placement Of US$3 Million 29
Oxygen Biotherapeutics Completes Private Placement Of Unregistered Convertible Notes For US$4.9 Million 31
Oxygen Biotherapeutics, Inc., Key Competitors 32
Oxygen Biotherapeutics, Inc., Key Employees 33
Oxygen Biotherapeutics, Inc., Other Locations 34

List of Figures

Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2008 to YTD 2014 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 4
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2008 to YTD 2014 5
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Region, 2008 to YTD 2014 6
Oxygen Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2008 to YTD 2014 7
Oxygen Biotherapeutics, Inc., Medical Devices Deals, 2008 to YTD 2014 8

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Sarepta Therapeutics, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.